Clinical Trial: Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers

U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07206043) titled 'Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers' on Sept. 26.

Brief Summary: The purpose of this study is to evaluate the safety, immunogenicity and pharmacokinetics of RPH-104 after single intravenous and subcutaneous administration to healthy volunteers at different doses

Study Start Date: Dec. 03, 2024

Study Type: INTERVENTIONAL

Condition: Healthy

Intervention: BIOLOGICAL: RPH-104 80 mg

solution for intravenous injection, 40 mg/mL

BIOLOGICAL: RPH-104 160 mg

solution for intravenous injection, 40 mg/mL

B...